Dietary Approach to Improving Quality of Life in Amyotrophic Lateral Sclerosis
NCT ID: NCT03659422
Last Updated: 2019-06-14
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
NA
Study Classification
INTERVENTIONAL
Study Start Date
2019-07-01
Study Completion Date
2021-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We have had reports of an individual who utilized a modified Paleolithic diet and vitamin/ supplement program as part of his approach to managing ALS related symptoms. This individual has experienced stability in his ALS functional rating score and stable to improving strength over an 18 month period. There are also anecdotal reports of ALS patients who have utilized a dietary approach based on a Paleolithic eating plan of improved function. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Tolerability Ultra-high-caloric Food Supplements in Amyotrophic Lateral Sclerosis (ALS)
NCT04172792
Amyotrophic Lateral Sclerosis
COMPLETED
PHASE1
The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT04140136
Amyotrophic Lateral Sclerosis
UNKNOWN
PHASE2
Ultra-high-caloric, Fatty Diet in ALS
NCT06280079
Amyotrophic Lateral Sclerosis
RECRUITING
NA
Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT00714220
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
TERMINATED
Oral Nutritional Supplementation in Amyotrophic Lateral Sclerosis (ALS) Patients
NCT02152449
Amyotrophic Lateral Sclerosis (ALS)
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study visits: 3 total over 12 weeks. Screening prior to enrollment will include consent to complete three 24-hour dietary recalls prior to the first study visit.
Visit 0. Subject will be seen in the University of Iowa Hospitals and Clinics (UIHC) Neurology Clinic, prevention intervention center or clinical research unit to review the consent, answer questions and sign the consent.
Subjects will provide phone numbers and best times for the dietitian to call for the dietary recall interviews and will be given a 2-dimensional food portion booklet to assist with reporting amount of food eaten.
Letters and a copy of the study consent will be sent to eligible ALS patients from the UIHC ALS clinic with follow up calls as previously descried.
Questions will be answered, the consent will be reviewed. If the patient wants to participate in the study, a Visit 1 will be scheduled and permission to complete the 24 hour dietary recalls will be obtained.
Height and weight will be documented from the participant clinic visits (neurology and primary care if needed) to obtain at least 2 weights and a height obtained in a clinic setting in the prior 6 months to calculate a slope of projected weight loss per month and a projected weight loss and muscle mass loss that may be observed at visit 2.
Visit 1. Subjects will be asked to fast for 12 hours prior to visit. Urine specific gravity will be obtained. The target is 1.004 to 1.028. If the urine is too dilute, the patient is to stop drinking and the other tests will be obtained and urine specific gravity will be repeated. The urine specific gravity that is noted that is within the range -- will be the target specific gravity for future BIS tests (ideally within .005). Patients are asked to report with the same level of hydration for future tests. Resting energy expenditure, forced vitality capacity and hand grip test will be completed. Fasting blood specimens and vital signs will be obtained. Subjects will be provided with a snack (or asked to bring a snack). Questionnaires will be completed. Subjects will be educated how the subject's personal family history (genetic vulnerability) may have interacted with the patient's unique DNA and lifetime of diet, lifestyle choices and environmental exposures to contributed to the participants' current health circumstances. The subject will be instructed on a stress-reducing practice on mindfulness and the subject will do a practice session of mindfulness. The participant will be taught the study diet by the intervention dietitian. A diet checklist that offers guidance to the subject in the form of prompts to eat the foods that are recommended and to avoid those that are not recommended will be provided. The subject and their adult companion will be given a study-compliant meal and will practice recording the meal in the diet checklist to facilitate the learning of the principles of the study diet and how to use the daily diet checklist. The subject and adult companion will be instructed on mindful eating.
The study visit will take approximately 5 to 6 hours. The subject will be given a 'loaner' food blending machine to use to make smoothies and soups that are compliant with the study diet. The subject will be asked to add 20 grams of bone broth protein powder and consume that in a study compliant smoothie or warm beverage each day to increase protein intake in a food or beverage item that does not require chewing (such as a smoothie or soup.
After the study visit:
Subjects will work by telephone with the study dietitian as they implement the study diet and stress reducing practice. The subject will be called 2 to 3 days after the visit by the study dietitian to review the study diet and answer questions. The dietitian will call again in one week to review the study diet with the study subject and ask how the participant is managing the diet. The dietitian will ask the participant if they are willing to continue on the study diet for the remainder of the study which is called the intervention phase of the study. If he participant is willing to continue the study diet, they will begin adding the various vitamins and supplements according to schedule in the diet checklist. If the participant does not wish to continue the study diet, the coaching calls will stop. Even if the participant resumes their usual diet, the participant will still come in for the end of study visit 3 at 12 weeks. The participant will not come back for 12 week visit.
Visit 2: 6 weeks.
Subjects will be asked to fast for 12 hours prior to visit. The patient will be weighed. Urine specific gravity will be obtained. The target urine specific gravity for the patient future BIS tests (ideally within .005) from the first BIS will be identified. A urine sample will be obtained The urine specific gravity will be obtained and compared to the target value. If the urine is too dilute, the patient is to stop drinking and the other tests will be obtained and urine specific gravity will be repeated in 1 hour.
The changes in muscle mass between visit 1 and visit 2 will be calculated and compared to the projected muscle mass loss. If the participant has lost more muscle mass than was projected, the study dietitian will instruct the participant on strategies to increase calories and protein while following the study diet. In addition, the participant will be asked to increase the intake of bone broth protein to 40 grams per day.
This visit will take 3 hours.
Visit 3: End of Study visit at 12 weeks. Participants will return the blending machine. The target urine specific gravity for the patient future BIS tests (ideally within .005) from the first BIS will be identified. A urine sample will be obtained The urine specific gravity will be obtained and compared to the target value. If the urine is too dilute, the patient is to stop drinking and the other tests will be obtained and urine specific gravity will be repeated in 1 hour. Patients are asked to report with the same level of hydration for future tests.
Resting energy expenditure, forced vitality capacity and BIS will be completed. Fasting blood specimens and vital signs will be obtained. Subjects will be able to eat a snack. The hand grip test will be completed. Questionnaires will be completed. The study team will answer questions about the study. Three 24 hour recalls will be completed in the week before and or the week after the end of study visit.
The changes in muscle mass between visit 1 and visit 2 will be calculated and compared to the projected muscle mass loss. The participant will be informed if the muscle mass is greater than projected and will be informed of strategies to increase calorie and protein intake.
The study visit will take approximately 2 to 3 hours.
Visit 0. Subject will be seen in the University of Iowa Hospitals and Clinics (UIHC) Neurology Clinic, prevention intervention center or clinical research unit to review the consent, answer questions and sign the consent.
Subjects will provide phone numbers and best times for the dietitian to call for the dietary recall interviews and will be given a 2-dimensional food portion booklet to assist with reporting amount of food eaten.
Letters and a copy of the study consent will be sent to eligible ALS patients from the UIHC ALS clinic with follow up calls as previously descried.
Questions will be answered, the consent will be reviewed. If the patient wants to participate in the study, a Visit 1 will be scheduled and permission to complete the 24 hour dietary recalls will be obtained.
Height and weight will be documented from the participant clinic visits (neurology and primary care if needed) to obtain at least 2 weights and a height obtained in a clinic setting in the prior 6 months to calculate a slope of projected weight loss per month and a projected weight loss and muscle mass loss that may be observed at visit 2.
Visit 1. Subjects will be asked to fast for 12 hours prior to visit. Urine specific gravity will be obtained. The target is 1.004 to 1.028. If the urine is too dilute, the patient is to stop drinking and the other tests will be obtained and urine specific gravity will be repeated. The urine specific gravity that is noted that is within the range -- will be the target specific gravity for future BIS tests (ideally within .005). Patients are asked to report with the same level of hydration for future tests. Resting energy expenditure, forced vitality capacity and hand grip test will be completed. Fasting blood specimens and vital signs will be obtained. Subjects will be provided with a snack (or asked to bring a snack). Questionnaires will be completed. Subjects will be educated how the subject's personal family history (genetic vulnerability) may have interacted with the patient's unique DNA and lifetime of diet, lifestyle choices and environmental exposures to contributed to the participants' current health circumstances. The subject will be instructed on a stress-reducing practice on mindfulness and the subject will do a practice session of mindfulness. The participant will be taught the study diet by the intervention dietitian. A diet checklist that offers guidance to the subject in the form of prompts to eat the foods that are recommended and to avoid those that are not recommended will be provided. The subject and their adult companion will be given a study-compliant meal and will practice recording the meal in the diet checklist to facilitate the learning of the principles of the study diet and how to use the daily diet checklist. The subject and adult companion will be instructed on mindful eating.
The study visit will take approximately 5 to 6 hours. The subject will be given a 'loaner' food blending machine to use to make smoothies and soups that are compliant with the study diet. The subject will be asked to add 20 grams of bone broth protein powder and consume that in a study compliant smoothie or warm beverage each day to increase protein intake in a food or beverage item that does not require chewing (such as a smoothie or soup.
After the study visit:
Subjects will work by telephone with the study dietitian as they implement the study diet and stress reducing practice. The subject will be called 2 to 3 days after the visit by the study dietitian to review the study diet and answer questions. The dietitian will call again in one week to review the study diet with the study subject and ask how the participant is managing the diet. The dietitian will ask the participant if they are willing to continue on the study diet for the remainder of the study which is called the intervention phase of the study. If he participant is willing to continue the study diet, they will begin adding the various vitamins and supplements according to schedule in the diet checklist. If the participant does not wish to continue the study diet, the coaching calls will stop. Even if the participant resumes their usual diet, the participant will still come in for the end of study visit 3 at 12 weeks. The participant will not come back for 12 week visit.
Visit 2: 6 weeks.
Subjects will be asked to fast for 12 hours prior to visit. The patient will be weighed. Urine specific gravity will be obtained. The target urine specific gravity for the patient future BIS tests (ideally within .005) from the first BIS will be identified. A urine sample will be obtained The urine specific gravity will be obtained and compared to the target value. If the urine is too dilute, the patient is to stop drinking and the other tests will be obtained and urine specific gravity will be repeated in 1 hour.
The changes in muscle mass between visit 1 and visit 2 will be calculated and compared to the projected muscle mass loss. If the participant has lost more muscle mass than was projected, the study dietitian will instruct the participant on strategies to increase calories and protein while following the study diet. In addition, the participant will be asked to increase the intake of bone broth protein to 40 grams per day.
This visit will take 3 hours.
Visit 3: End of Study visit at 12 weeks. Participants will return the blending machine. The target urine specific gravity for the patient future BIS tests (ideally within .005) from the first BIS will be identified. A urine sample will be obtained The urine specific gravity will be obtained and compared to the target value. If the urine is too dilute, the patient is to stop drinking and the other tests will be obtained and urine specific gravity will be repeated in 1 hour. Patients are asked to report with the same level of hydration for future tests.
Resting energy expenditure, forced vitality capacity and BIS will be completed. Fasting blood specimens and vital signs will be obtained. Subjects will be able to eat a snack. The hand grip test will be completed. Questionnaires will be completed. The study team will answer questions about the study. Three 24 hour recalls will be completed in the week before and or the week after the end of study visit.
The changes in muscle mass between visit 1 and visit 2 will be calculated and compared to the projected muscle mass loss. The participant will be informed if the muscle mass is greater than projected and will be informed of strategies to increase calorie and protein intake.
The study visit will take approximately 2 to 3 hours.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Diet Modification
Amyotrophic Lateral Sclerosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Arm
Modified Paleolithic diet and vitamin/ supplement program was part of previous approaches to managing ALS related symptoms over an 18 month period. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
Group Type
OTHER
Modified Paleolithic diet
Intervention Type
OTHER
The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modified Paleolithic diet
The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Diagnosis of clinically possible, clinically probable (with or without laboratory support), or clinically definite ALS (using the revised El Escorial Criteria)
2. Ability to prepare, or have prepared for them, home-cooked meals
3. Age between 18 and 80 years
4. Followed by ALS clinic at the University of Iowa
5. Willingness to adopt the study diet
2. Ability to prepare, or have prepared for them, home-cooked meals
3. Age between 18 and 80 years
4. Followed by ALS clinic at the University of Iowa
5. Willingness to adopt the study diet
Exclusion Criteria
1. Clinically significant liver, kidney, or heart disease
2. Taking insulin or Coumadin
3. Ventilator dependence
4. Psychiatric disorder making dietary compliance difficult (e.g. schizophrenia)
5. Unwillingness to have blood specimens collected
6. Dysphagia present
7. Greater than two years since onset of ALS symptoms
2. Taking insulin or Coumadin
3. Ventilator dependence
4. Psychiatric disorder making dietary compliance difficult (e.g. schizophrenia)
5. Unwillingness to have blood specimens collected
6. Dysphagia present
7. Greater than two years since onset of ALS symptoms
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Muscular Dystrophy Association
OTHER
Sponsor Role
collaborator
Terry L. Wahls
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Terry L. Wahls
Clinical Professor of Medicine, Principal Investigator
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Terry L Wahls, MD
Role: PRINCIPAL_INVESTIGATOR
University of Iowa
References
Explore related publications, articles, or registry entries linked to this study.
Milonas I. Amyotrophic lateral sclerosis: an introduction. J Neurol. 1998 Aug;245 Suppl 2:S1-3. doi: 10.1007/s004150050640.
Reference Type
BACKGROUND
Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225-38. doi: 10.1016/B978-0-12-802973-2.00013-6.
Reference Type
BACKGROUND
Wang MD, Little J, Gomes J, Cashman NR, Krewski D. Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology. 2017 Jul;61:101-130. doi: 10.1016/j.neuro.2016.06.015. Epub 2016 Jul 1.
Reference Type
BACKGROUND
Okamoto K, Kihira T, Kobashi G, Washio M, Sasaki S, Yokoyama T, Miyake Y, Sakamoto N, Inaba Y, Nagai M. Fruit and vegetable intake and risk of amyotrophic lateral sclerosis in Japan. Neuroepidemiology. 2009;32(4):251-6. doi: 10.1159/000201563. Epub 2009 Feb 11.
Reference Type
BACKGROUND
Jin Y, Oh K, Oh SI, Baek H, Kim SH, Park Y. Dietary intake of fruits and beta-carotene is negatively associated with amyotrophic lateral sclerosis risk in Koreans: a case-control study. Nutr Neurosci. 2014 Apr;17(3):104-8. doi: 10.1179/1476830513Y.0000000071. Epub 2013 Nov 26.
Reference Type
BACKGROUND
Fitzgerald KC, O'Reilly EJ, Falcone GJ, McCullough ML, Park Y, Kolonel LN, Ascherio A. Dietary omega-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol. 2014 Sep;71(9):1102-10. doi: 10.1001/jamaneurol.2014.1214.
Reference Type
BACKGROUND
Appel SH, Smith RG, Engelhardt JI, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci. 1994 Jul;124 Suppl:14-9. doi: 10.1016/0022-510x(94)90171-6.
Reference Type
BACKGROUND
Appel SH, Smith RG, Engelhardt JI, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci. 1993 Sep;118(2):169-74. doi: 10.1016/0022-510x(93)90106-9.
Reference Type
BACKGROUND
Brown KJ, Jewells V, Herfarth H, Castillo M. White matter lesions suggestive of amyotrophic lateral sclerosis attributed to celiac disease. AJNR Am J Neuroradiol. 2010 May;31(5):880-1. doi: 10.3174/ajnr.A1826. Epub 2009 Nov 12.
Reference Type
BACKGROUND
Gadoth A, Nefussy B, Bleiberg M, Klein T, Artman I, Drory VE. Transglutaminase 6 Antibodies in the Serum of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2015 Jun;72(6):676-81. doi: 10.1001/jamaneurol.2015.48.
Reference Type
BACKGROUND
Rao TV, Tharakan JK, Jacob PC. Systemic lupus erythematosus presenting as amyotrophic lateral sclerosis. Clin Neuropathol. 2004 May-Jun;23(3):99-101.
Reference Type
BACKGROUND
Maldonado ME, Williams RC Jr, Adair JC, Hart BL, Gregg L, Sibbitt WL Jr. Neuropsychiatric systemic lupus erythematosus presenting as amyotrophic lateral sclerosis. J Rheumatol. 2002 Mar;29(3):633-5.
Reference Type
BACKGROUND
Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology. 2013 Oct 1;81(14):1222-5. doi: 10.1212/WNL.0b013e3182a6cc13. Epub 2013 Aug 14.
Reference Type
BACKGROUND
Park Y, Park J, Kim Y, Baek H, Kim SH. Association between nutritional status and disease severity using the amyotrophic lateral sclerosis (ALS) functional rating scale in ALS patients. Nutrition. 2015 Nov-Dec;31(11-12):1362-7. doi: 10.1016/j.nut.2015.05.025. Epub 2015 Jul 6.
Reference Type
BACKGROUND
Bouteloup C, Desport JC, Clavelou P, Guy N, Derumeaux-Burel H, Ferrier A, Couratier P. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009 Aug;256(8):1236-42. doi: 10.1007/s00415-009-5100-z. Epub 2009 Mar 22.
Reference Type
BACKGROUND
Roubeau V, Blasco H, Maillot F, Corcia P, Praline J. Nutritional assessment of amyotrophic lateral sclerosis in routine practice: value of weighing and bioelectrical impedance analysis. Muscle Nerve. 2015 Apr;51(4):479-84. doi: 10.1002/mus.24419. Epub 2015 Feb 24.
Reference Type
BACKGROUND
Ngo ST, Steyn FJ, McCombe PA. Body mass index and dietary intervention: implications for prognosis of amyotrophic lateral sclerosis. J Neurol Sci. 2014 May 15;340(1-2):5-12. doi: 10.1016/j.jns.2014.02.035. Epub 2014 Mar 3.
Reference Type
BACKGROUND
Salvioni CC, Stanich P, Almeida CS, Oliveira AS. Nutritional care in motor neurone disease/ amyotrophic lateral sclerosis. Arq Neuropsiquiatr. 2014 Feb;72(2):157-63. doi: 10.1590/0004-282X20130185.
Reference Type
BACKGROUND
Fitzgerald KC, O'Reilly EJ, Fondell E, Falcone GJ, McCullough ML, Park Y, Kolonel LN, Ascherio A. Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: pooled results from 5 cohort studies. Ann Neurol. 2013 Feb;73(2):236-45. doi: 10.1002/ana.23820. Epub 2013 Jan 29.
Reference Type
BACKGROUND
Bisht B, Darling WG, Grossmann RE, Shivapour ET, Lutgendorf SK, Snetselaar LG, Hall MJ, Zimmerman MB, Wahls TL. A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. J Altern Complement Med. 2014 May;20(5):347-55. doi: 10.1089/acm.2013.0188. Epub 2014 Jan 29.
Reference Type
BACKGROUND
Lee JE, Bisht B, Hall MJ, Rubenstein LM, Louison R, Klein DT, Wahls TL. A Multimodal, Nonpharmacologic Intervention Improves Mood and Cognitive Function in People with Multiple Sclerosis. J Am Coll Nutr. 2017 Mar-Apr;36(3):150-168. doi: 10.1080/07315724.2016.1255160. Epub 2017 Apr 10.
Reference Type
BACKGROUND
Coyne N, Correnti D. Effectiveness of motivational interviewing to improve chronic condition self-management: what does the research show us? Home Healthc Nurse. 2014 Jan;32(1):56-63. doi: 10.1097/NHH.0000000000000001.
Reference Type
BACKGROUND
Vansteenkiste M, Williams GC, Resnicow K. Toward systematic integration between self-determination theory and motivational interviewing as examples of top-down and bottom-up intervention development: autonomy or volition as a fundamental theoretical principle. Int J Behav Nutr Phys Act. 2012 Mar 2;9:23. doi: 10.1186/1479-5868-9-23.
Reference Type
BACKGROUND
Inam S, Vucic S, Brodaty NE, Zoing MC, Kiernan MC. The 10-metre gait speed as a functional biomarker in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 Dec;11(6):558-61. doi: 10.3109/17482961003792958. Epub 2010 Jun 2.
Reference Type
BACKGROUND
Martin JL, Hakim AD. Wrist actigraphy. Chest. 2011 Jun;139(6):1514-1527. doi: 10.1378/chest.10-1872.
Reference Type
BACKGROUND
Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005 Jan 11;64(1):38-43. doi: 10.1212/01.WNL.0000148648.38313.64.
Reference Type
BACKGROUND
Simmons Z, Felgoise SH, Bremer BA, Walsh SM, Hufford DJ, Bromberg MB, David W, Forshew DA, Heiman-Patterson TD, Lai EC, McCluskey L. The ALSSQOL: balancing physical and nonphysical factors in assessing quality of life in ALS. Neurology. 2006 Nov 14;67(9):1659-64. doi: 10.1212/01.wnl.0000242887.79115.19.
Reference Type
BACKGROUND
Chio A, Gauthier A, Calvo A, Ghiglione P, Mutani R. Caregiver burden and patients' perception of being a burden in ALS. Neurology. 2005 May 24;64(10):1780-2. doi: 10.1212/01.WNL.0000162034.06268.37.
Reference Type
BACKGROUND
Bisht B, Darling WG, Shivapour ET, Lutgendorf SK, Snetselaar LG, Chenard CA, Wahls TL. Multimodal intervention improves fatigue and quality of life in subjects with progressive multiple sclerosis: a pilot study. Degener Neurol Neuromuscul Dis. 2015;5:19-35. doi: 10.2147/DNND.S76523. Epub 2015 Feb 27.
Reference Type
BACKGROUND
Irish AK, Erickson CM, Wahls TL, Snetselaar LG, Darling WG. Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study. Degener Neurol Neuromuscul Dis. 2017 Jan 4;7:1-18. doi: 10.2147/DNND.S116949. eCollection 2017.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201802746
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation
NCT00116558
COMPLETED
NA
Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients
NCT03326622
COMPLETED
NA
Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype
NCT01823380
COMPLETED
NA
Determining the Safety of L-serine in ALS
NCT01835782
UNKNOWN
PHASE1/PHASE2
Mitochondrial Functions and Oxidative Stress in ALS Patients
NCT00331812
UNKNOWN
Evaluating the Potential of the Diet as Disease Modifier in Amyotrophic Lateral Sclerosis (JERN_ALS)
NCT02572479
COMPLETED
Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01933321
COMPLETED
PHASE2/PHASE3
DIAGALS: Relation Between Tar DNA Binding Protein(TDP)-43 et Nrf-2 in ALS: a Track to Improve Diagnosis and Prognosis of the Disease
NCT06230562
UNKNOWN
NA
Study of the Effects Strengthening Exercises in Individuals With ALS
NCT00204464
COMPLETED
PHASE2
Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis
NCT01082653
SUSPENDED
PHASE1
Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)
NCT01016522
TERMINATED
PHASE3
potentiALS - Quality of Life Among Patients With Amyotrophic Lateral Sclerosis
NCT06441448
RECRUITING
High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis
NCT00983983
COMPLETED
PHASE2
Effects of Gastrostomy on Amyotrophic Lateral Sclerosis
NCT00337402
COMPLETED
Study of ALS Reversals 4: LifeTime Exposures
NCT03706391
COMPLETED
A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS
NCT03324399
COMPLETED
NA
Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis
NCT01592084
COMPLETED
Examining Interactions Between PALS and Caregivers
NCT06819124
RECRUITING
NA
The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis
NCT00160004
TERMINATED
PHASE1/PHASE2
Clinical Trial of High Dose CoQ10 in ALS
NCT00243932
COMPLETED
PHASE2
Amyotrophic Lateral Sclerosis (ALS) Families Project
NCT03865420
RECRUITING
Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis
NCT02588807
WITHDRAWN
PHASE1
Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis
NCT02528071
TERMINATED
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis
NCT06391645
NOT_YET_RECRUITING
PHASE2/PHASE3
Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT01142856
COMPLETED
PHASE1